| Literature DB >> 36262834 |
Duoxi Duan1, Lin He2, Hong Chen1, Ying Lei1, Wei Wu3, Tao Li1.
Abstract
Background: Children with autism spectrum disorders (ASDs) suffer from sleep disorders to a considerable degree; however, there is no safe and effective treatment available in clinical practice. The objective of the trial is to assess the clinical effectiveness of auricular plaster therapy (APT) in treating sleep disorders in children with ASD. Method: This is a single-center, patient-assessor blind, randomized controlled trial. A total of 44 preschool children with sleep disorders with ASD will be included in this study. Eligible participants will be randomly assigned to either the auricular plaster group or the sham auricular plaster group in a 1:1 ratio. Participants in the different groups will receive APT or sham APT, respectively, for a total of 30 sessions over 30 days. The primary outcome includes the Children's Sleep Habits Questionnaire (CSHQ), while secondary outcomes include the Autism Behavior Checklist (ABC) and polysomnography (PSG) for total sleep time, sleep latency, awakening duration, and sleep structures. The CSHQ and ABC will be assessed at baseline, 10, 20, 30, 60, 90, and 120 days after randomization, whereas PSG will be assessed at baseline and 30 days after randomization. The follow-up period will be scheduled to be 60, 90, and 120 days after randomization. Discussion: The results of this study may provide evidence of the efficacy of APT, as well as offer new alternatives for the treatment of sleep disorders in children with ASD. Trial registration: CHiCTR.org.cn (ChiCTR2100048257). Registered on July 5, 2021.Entities:
Keywords: auricular plaster therapy; autism; preschool children; sleep disorders; study protocol
Year: 2022 PMID: 36262834 PMCID: PMC9574001 DOI: 10.3389/fneur.2022.973609
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Summary of clinical guidelines for the treatment of sleep disorders in children with autism spectrum disorders.
|
|
|
|---|---|
| 2021 NICE guideline | Not mentioned |
| 2020 AAN guideline | Behavioral strategies are first-line treatment approach (Level B). |
| 2017 BAP guideline | Melatonin, if possible, in combination with a behavioral intervention (Strength of recommendation: A). |
| 2017 NICE guideline | Not mentioned |
| 2013 NICE guideline | Not mentioned |
NICE, National Institute for Health and Care Excellence; ASD, autism spectrum disorders; AAN, American Academy of Neurology; BAP, British Association for Psychopharmacology; GABA, gamma-aminobutyric acid.
Randomized controlled trials of sleep disorders in children with autism spectrum disorders.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Hayashi et al. ( | Japan | Multicenter | Melatonin | Placebo | 196 | Double blind | Sleep onset latency | Melatonin is effective for sleep disorders. |
| Ansari et al. ( | Iran | Single | Aquatic exercise | None | 40 | Not mentioned | CSHQ | Aquatic exercise may improve sleep quality and reduce the serum IL-1β and TNF-α. |
| Papadopoulos et al. ( | Australia | Single | Sleep behavioral intervention | Usual clinical care | 61 | Not mentioned | CSHQ | A brief behavioral sleep intervention can improve sleep problems. |
| Reynolds et al. ( | USA | Single | Ferrous sulfate | Placebo | 20 | Double blind | Bedtime and wake time | No improvement in insomnia in treated with ferrous sulfate. |
| Mehrazad-Saber et al. ( | Iran | Single | Carnosine | Placebo | 43 | Double blind | CSHQ | Carnosine could be effective in improving sleep disorders. |
| Gringras et al. ( | USA | Single | PedPRM | Placebo | 125 | Double blind | SND and CSDI | PedPRM is effective and safe for treatment of insomnia. |
| Frazier et al. ( | USA | Single | Pre-STS mattress | After-STS mattress | 45 | Double blind | Sleep diary | STS could improve sleep duration and sleep efficiency. |
| Gringras et al. ( | USA | Single | Weighted blankets | Placebo | 73 | Not mentioned | TST | The use of a weighted blanket does not help children with ASD sleep. |
| Johnson et al. ( | USA | Single | BPT program for parents | Not BPT | 40 | Not mentioned | Treatment fidelity checklist | BPT has a certain effect on sleep disorders. |
| Cortesi et al. ( | Italy | Single | CBT and melatonin | Melatonin or Placebo | 160 | Double blind | Sleep variables* | In the short term, CBT and melatonin have efficacy for sleep disorders |
| Adkins et al. ( | USA | Single | Sleep education to parents | No sleep education | 36 | Not mentioned | Changes in sleep latency | The sleep education pamphlet did not improve sleep latency. |
| Wright et al. ( | UK | Single | Melatonin | Placebo | 22 | Double blind | Sleep variables† | Melatonin improved sleep latency and total sleep but not number of night awakenings. |
| Wirojanan et al. ( | USA | Single | Melatonin | Placebo | 12 | Double blind | Sleep variables‡ | The efficacy and tolerability of melatonin treatment for sleep problems can be affirmed. |
| Garstang and Wallis ( | UK | Single | Melatonin | Placebo | 11 | Double blind | Sleep variables¶ | Melatonin was beneficial for sleep disorders. |
CSHQ, children's sleep habits questionnaire; TNF, tumor necrosis factor; PedPRM, prolonged-release melatonin minitablets; SND, sleep and nap diary; CSDI, composite sleep disturbance index; STS, sound-to-sleep; TST, total sleep time; BPT, behavioral parent training; CBT, cognitive behavioral therapy.
*Represents sleep latency, total sleep time, wake after sleep onset, and the number of awakenings in sleep variables.
†Represents sleep latency, total sleep, and night awakening in sleep variables.
‡Represents sleep-onset time, total night sleep duration, sleep-onset latency time, and the number of night awakenings in sleep variables.
¶Represents sleep latency, number of awakenings, and total sleep duration in sleep variables.
Figure 1Study flowchart.
Study schedule of the trial.
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| Eligibility screen |
| ||||||||
| Informed consent |
| ||||||||
| Allocation |
| ||||||||
|
| |||||||||
| Auricular plaster |
| ||||||||
| Sham auricular plaster |
| ||||||||
|
| |||||||||
| CSHQ |
|
|
|
|
|
|
| ||
| ABC |
|
|
|
|
|
|
| ||
| PSG |
|
| |||||||
| AEs |
|
|
| ||||||
CSHQ, Children's Sleep Habits Questionnaire; ABC, Autism Behavior Checklist; PSG, polysomnography; AES, adverse events.
Locations of auricular points.
|
|
|
|---|---|
| Heart (CO15) | Located at the middle of the concha |
| Jiaogan (AH6a) | Located at the junction of the front end of the lower part of the antihelix and the inner edge of the helix |
| Shenmen (TF4) | Located at the upper of the posterior third of the triangular fossa |
| Subcortex (AT4) | Located at the medial side of the antitragus |
| Kidney (CO10) | Located at the rear of the lower part of the antihelix |
| Spleen (CO13) | Located at the posterior upper part of the concha |
Figure 2Location of auricular acupoints.